Skip to main content
. Author manuscript; available in PMC: 2007 Sep 17.
Published in final edited form as: J Am Soc Nephrol. 2007 Apr 4;18(5):1576–1583. doi: 10.1681/ASN.2006111263

Figure 3.

Figure 3

The effect of EOW and weekly agalsidase alfa on urine sediment globotriaosylceramide (Gb3) in male patients with Fabry disease. Pre indicates value before the start of EOW dosing. The individual symbols represent the same patients depicted in Figure 1.